These peptides were able to increase the survival time of TC-1 tumor-bearing mice after therapeutic vaccination with an HPV16E7 peptide-based vaccine containing IL-10 inhibitor via increased recruitment of T cells to the tumor site, probably by TC-1-promoted secretion of proinflammatory IL-6 [78]. Here, IL10 is linked to neoplasm.